Preparation method of monomeric protein and hydrophobic transmembrane protein complex
By regulating the link length between monomeric proteins and hydrophobic transmembrane proteins through TEV enzyme cleavage and Sortase A enzyme ligation, the problem of single link length in existing technologies is solved, enabling flexible adjustment and high-purity preparation of complex proteins.
Patent Information
- Application Number
- CN202511042085.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-28
- Publication Date
- 2025-10-31
AI Technical Summary
In existing technologies, the connection length of the complex formed by monomeric proteins and hydrophobic transmembrane proteins is limited, which restricts the functional realization of the complex protein and reduces the degree of adjustment.
By preparing protein A, which contains a monomeric protein, and protein B, which contains a hydrophobic transmembrane protein, and then using TEV enzyme cleavage and Sortase A enzyme ligation to adjust the ligation length, a complex of monomeric protein and hydrophobic transmembrane protein is formed.
It enables flexible adjustment of the connection length to meet the needs of different application scenarios, maintains protein activity, and improves the purity and functional diversity of the complex through purification steps.
Smart Images

Figure CN120865437A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology, specifically relating to a method for preparing a complex of monomeric protein and hydrophobic transmembrane protein. Background Technology
[0002] Hydrophobic transmembrane proteins are a class of functional proteins that embed themselves in the lipid bilayer of the cell membrane through hydrophobic amino acid regions, playing a central role in life activities such as substance transport and signal transduction. Their biological functions include: substance transport, forming selective channels or carriers; transmitting extracellular signals, such as stimuli like light and hormones, through conformational changes in transmembrane regions; and mediating cell-cell interactions and maintaining tissue structure through transmembrane adhesion proteins. The roles of hydrophobic transmembrane proteins in the DNA polymerase complex include nuclear membrane localization regulation, construction of damage repair environments, and coupling of replication forks.
[0003] Currently, the methods for linking monomeric proteins and hydrophobic transmembrane proteins into complexes are usually through spy-tag-spy-catcher linkage or by using chemically modified Click reactions. For example, the linking of polymerases and nanopore complexes is often done by spy-tag-spy-catcher linkage. The disadvantage is that the linkage length is relatively limited, which leads to limitations in the functional realization of the protein in the linked complex and a relatively small degree of controllability. Summary of the Invention
[0004] This method proposes a way to prepare a complex of monomeric protein and hydrophobic transmembrane protein to solve the problem of the single link length of monomeric protein and hydrophobic transmembrane protein. The above objective can be achieved through the following technical solutions:
[0005] A method for preparing a complex of a monomeric protein and a hydrophobic transmembrane protein includes the following steps:
[0006] Step 1) Prepare protein A comprising the monomeric protein, wherein the C-terminus of the monomeric protein in protein A has a linker sequence for linking with a hydrophobic transmembrane protein; the linker sequence comprises at least 2 amino acids;
[0007] Prepare protein B containing hydrophobic transmembrane protein monomers;
[0008] Step 2) Connect protein A and protein B, and polymerize multiple hydrophobic transmembrane protein monomers in protein B to form a hydrophobic transmembrane protein, thereby obtaining a monomeric protein and a hydrophobic transmembrane protein complex.
[0009] Optionally, in step one), the C-terminus of the monomeric protein A in protein A is connected to a C-terminal modification sequence, the C-terminal modification sequence including a first length regulation sequence and a recognition site of Sortase A;
[0010] The N-terminus of the hydrophobic transmembrane protein in protein B is connected to an N-terminal modification sequence, which includes a TEV restriction site and a second length regulation sequence.
[0011] Protein B has a transition sequence at its C-terminus, which is a purified tag sequence linked to a TEV restriction site;
[0012] In step two), protein B is first cleaved using TEV protease to obtain cleaved protein B; then protein A and cleaved protein B are reacted with Sortase enzyme to link the first length regulation sequence and the second length regulation sequence to form the linking sequence; and the hydrophobic transmembrane protein monomers in multiple cleaved proteins B are polymerized to form a hydrophobic transmembrane protein, resulting in a monomeric protein and a hydrophobic transmembrane protein complex.
[0013] Optionally, the monomeric protein is DNA polymerase Phi29, the amino acid sequence of protein A is shown in SEQ ID NO.7, and the amino acid sequence of protein B is shown in SEQ ID NO.8;
[0014] Preferably, the C-terminus of the amino acid sequence of protein B has a TEV restriction site and a purification tag sequence.
[0015] Optionally, the preparation method of protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into a host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and sonicated to break them up, and the supernatant is collected; the supernatant is purified to obtain protein A or protein B.
[0016] Optionally, the nucleotide sequence of expressed protein A is shown in SEQ ID No. 3; and the nucleotide sequence of expressed protein B is shown in SEQ ID No. 4.
[0017] Optionally, in step one), protein A is a co-expressed fusion protein formed by tandemly linking a monomeric protein and a hydrophobic transmembrane protein monomer through the linking sequence;
[0018] Both protein A and protein B have a tag sequence linked to the C-terminus via a TEV restriction site.
[0019] In step two), protein A and protein B are first cleaved using TEV protease to obtain cleaved protein A and protein B; then the cleaved protein A and protein B are reacted to polymerize the hydrophobic transmembrane protein monomers in multiple cleaved protein B with the hydrophobic transmembrane protein monomers in protein A to form a hydrophobic transmembrane protein; thus obtaining a monomeric protein and a hydrophobic transmembrane protein complex.
[0020] Optionally, the amino acid sequence of protein A is shown in SEQ ID NO.5, and the amino acid sequence of protein B is shown in SEQ ID NO.6;
[0021] Preferably, the C-terminus of the amino acid sequences of proteins A and B has a TEV restriction site and a purification tag sequence.
[0022] Optionally, the preparation method of protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into a host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and sonicated to break them up, and the supernatant is collected; the supernatant is purified to obtain protein A or protein B.
[0023] Optionally, the nucleotide sequence of the expressed protein A is shown in SEQ ID No. 1; and the nucleotide sequence of the expressed protein B is shown in SEQ ID No. 2.
[0024] Optionally, step two may further include purifying and concentrating the monomeric protein and the hydrophobic transmembrane protein complex.
[0025] Compared with the prior art, the present invention has the following outstanding advantages:
[0026] This invention regulates the link length between monomeric proteins and hydrophobic transmembrane protein complexes through co-expression or Sortase A transpeptidase ligation, thereby maintaining enzyme activity. During Sortase A transpeptidase ligation, the modification lengths of the N-terminus and C-terminus can be autonomously adjusted as needed; during fusion expression, the link length between proteins can also be autonomously adjusted as required. This invention not only enables protein-protein linkage to form complexes but also allows for the design of expressed proteins to lengthen or shorten the link distance between proteins, adapting to different application scenarios. Attached Figure Description
[0027] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.
[0028] Figure 1 This is a graph showing the electrophoretic verification results of the complex in Example 1;
[0029] Figure 2 This is a graph showing the protein purification results of Example 1;
[0030] Figure 3This is a graph showing the electrophoretic verification results of the complex in Example 2;
[0031] Figure 4 The results are the activity test results of the complex enzymes in Examples 1 and 2. Detailed Implementation
[0032] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention. It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the present invention.
[0033] Furthermore, regarding the numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Any stated value or intermediate value within a stated range, as well as each smaller range between any other stated value or intermediate value within said range, are also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.
[0034] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar to or equivalent to those described herein may be used in the implementation or testing of this invention.
[0035] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.
[0036] This invention proposes a method for preparing a complex of monomeric protein and hydrophobic transmembrane protein, comprising the following steps:
[0037] Step 1) Prepare protein A comprising the monomeric protein, wherein the C-terminus of the monomeric protein in protein A has a linker sequence for linking with a hydrophobic transmembrane protein; the linker sequence comprises at least 2 amino acids;
[0038] Prepare protein B containing hydrophobic transmembrane protein monomers;
[0039] Step 2) Connect protein A and protein B, and polymerize multiple hydrophobic transmembrane protein monomers in protein B to form a hydrophobic transmembrane protein, thereby obtaining a monomeric protein and a hydrophobic transmembrane protein complex.
[0040] The aforementioned monomeric protein refers to a protein with a specific function, which, when combined with a hydrophobic transmembrane protein, forms a complex possessing that function. The aforementioned hydrophobic transmembrane protein monomer refers to the monomer used to compose the hydrophobic transmembrane protein; that is, several hydrophobic transmembrane protein monomers can combine to form a hydrophobic transmembrane protein.
[0041] Specifically, the following approaches can be adopted: The first is to modify the N-terminus and C-terminus of monomeric or complex proteins. The modification lengths at the N-terminus and C-terminus can be adjusted as needed. Then, the protein-protein linkage is achieved using the transpeptidase Sortase A. The second approach involves fusing monomeric proteins, such as DNA polymerase, RNA polymerase, and helicase, with monomeric complex proteins, such as nanoporous proteins, for co-expression, followed by purification. This co-expression is then combined with other monomeric proteins from a multi-polymer complex to form a large complex of monomers and oligomers. During fusion expression, the linkage length between proteins can be adjusted as needed. Specific examples are as follows:
[0042] Option 1 (Sortase A ligation system)
[0043] In this scheme, the C-terminus of the monomeric protein in protein A is attached with a C-terminal modification sequence, which includes a first length regulation sequence and a recognition site for Sortase A; the N-terminus of the hydrophobic transmembrane protein in protein B is attached with an N-terminal modification sequence, which includes a TEV restriction site and a second length regulation sequence.
[0044] Protein B has a transition sequence at its C-terminus, which is linked to a purification tag sequence via a TEV restriction site. The function of the transition sequence is to increase the degree of freedom between the target protein and the purification tag, so that the protein folding is not affected by the purification tag.
[0045] The connection method of proteins A and B is as follows: first, protein B is cleaved by TEV protease to obtain cleaved protein B; then, protein A and cleaved protein B are reacted with Sortase enzyme to connect the first length regulation sequence and the second length regulation sequence to form the connection sequence; and then, the hydrophobic transmembrane protein monomers in multiple cleaved proteins B are polymerized to form a hydrophobic transmembrane protein, resulting in a monomeric protein and a hydrophobic transmembrane protein complex.
[0046] The preparation method of the protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into the host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and ultrasonically broken up, and the supernatant is collected; the supernatant is purified to obtain the protein A or protein B.
[0047] This method specifically includes the following steps:
[0048] Step 1: Provide sequence information for gene expression; where protein A is a C-terminal modified Phi29 DNA polymerase protein, the nucleotide sequence of which is shown in SEQ ID No. 3, and the amino acid sequence of which is shown in SEQ ID No. 7. In its amino acid sequence, positions 1 to 575 are DNA polymerase Phi29, positions 576 to 584 are the first length regulation sequence, and positions 585 to 596 are the recognition site of Sortase A and the purification tag.
[0049] Protein B is an α-HL nanoporous protein monomer with an N-terminal amino-terminal modification. Its nucleotide sequence is shown in SEQ ID No. 4, and its amino acid sequence is shown in SEQ ID No. 8. In its amino acid sequence, positions 4-10 are TEV restriction sites, positions 11-22 are the second length regulation sequence, positions 23-318 are the nanoporous protein monomer, positions 319-325 are the transition sequence, positions 326-332 are the TEV restriction sites, and positions 333-340 are the purification tag.
[0050] Step 2: Ligate the gene expression sequence into the gene expression vector pET-30a via NdeI and BamHI restriction sites. + middle;
[0051] Step 3: Transform the gene expression vector into host cells BL21 to obtain recombinant cells;
[0052] Step 4: Induce expression in the recombinant cells and collect the bacterial cells;
[0053] Step 5: Sonicate the resuspended bacterial cells to disrupt them and collect the supernatant;
[0054] Step Six: Utilizing Ni 2+ Alternatively, the supernatant can be purified using a Strep affinity column, and the purified protein can be collected.
[0055] Step 7: Concentrate the protein described in Step 6 using an ultrafiltration column;
[0056] Step 8: The strep protein is cleaved by a TEV protease to remove the purification tag and release glycine protein with more than 5 N-terminal nucleotides. Then, it is ligated using Sortase A.
[0057] Step 9: Assemble a complex of the linker protein and multiple transmembrane hydrophobic protein monomers;
[0058] Step 10: Protein complex purification.
[0059] Option 2 (Fusion Protein Expression Ligation System)
[0060] In this scheme, protein A in step one) is a co-expressed fusion protein formed by the tandem linking of a monomeric protein and a hydrophobic transmembrane protein monomer through the linking sequence;
[0061] Both protein A and protein B have a tag sequence linked to the C-terminus via a TEV restriction site.
[0062] The connection method is as follows: first, protein A and protein B are cleaved by TEV protease to obtain cleaved protein A and protein B; then, the cleaved protein A and protein B react to polymerize the hydrophobic transmembrane protein monomers in multiple cleaved protein B with the hydrophobic transmembrane protein monomers in protein A to form a hydrophobic transmembrane protein; thus, a monomeric protein and a hydrophobic transmembrane protein complex are obtained.
[0063] Optionally, the amino acid sequence of protein A is shown in SEQ ID NO.5, and the amino acid sequence of protein B is shown in SEQ ID NO.6;
[0064] Optionally, the preparation method of protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into a host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and sonicated to break them up, and the supernatant is collected; the supernatant is purified to obtain protein A or protein B.
[0065] This method specifically includes the following steps:
[0066] Step 1: Provide sequence information for gene expression; Protein A is a fusion protein of DNA polymerase Phi29 and nanoporin monomer, with the nucleotide sequence shown in SEQ ID No. 1 and the amino acid sequence shown in SEQ ID No. 5. In its amino acid sequence, positions 1-575 represent DNA polymerase Phi29, positions 576-584 are the linker sequence, positions 585-881 represent the nanoporin monomer, positions 882-888 are the TEV restriction site, and positions 889-896 are the purification tag.
[0067] Protein B is a nanoporous monomer protein. Its nucleotide sequence is shown in SEQ ID No. 2, and its amino acid sequence is shown in SEQ ID No. 6. In its amino acid sequence, positions 1 to 298 are nanoporous protein monomers, positions 299 to 305 are TEV restriction sites, and positions 306 to 313 are purification tags.
[0068] Step 2: Ligate the gene expression sequence into the gene expression vector pET-30a via NdeI and BamHI restriction sites. + middle;
[0069] Step 3: Transform the gene expression vector into host cells BL21 to obtain recombinant cells;
[0070] Step 4: Induce expression in the recombinant cells and collect the bacterial cells;
[0071] Step 5: Sonicate the resuspended bacterial cells to disrupt them and collect the supernatant;
[0072] Step 6: Purify the supernatant using a Strep affinity column and collect the purified protein;
[0073] Step 7: Concentrate the protein described in Step 6 using an ultrafiltration column, and then perform a one-step TEV protease cleavage of the protein to remove the purification tag.
[0074] Step 8: Assemble the fusion-expressed protein with the separately expressed complex protein monomers;
[0075] Step 9: Protein complex purification.
[0076] Example 1
[0077] The gene expression sequences of SEQ ID NO.3 and SEQ ID NO.4 were transformed into E. coli competent cells BL21 (Shanghai Tulugang Biotechnology Co., Ltd., catalog number CC96107). After resistance screening, 5 μL of the inoculum was inoculated into 5 mL of LB broth and incubated overnight at 37°C with shaking. Then, it was transferred to 200 mL of LB broth and incubated at 37°C for 5 h with shaking. OD 600 When the concentration reaches 1, the bacterial culture is removed and cooled at 4°C. After cooling, IPTG is added to a final concentration of 0.6 mM for induction, and the culture is continued overnight at 20°C with shaking. Affinity chromatography is used for purification using a Ni column or a Strep-tagged column to obtain monomeric proteins and oligomeric monomeric proteins. The proteins are then concentrated using an AMICON ULTRA 15 mL 50K ultrafiltration column (Millipore, catalog number: UFC905024).
[0078] The strep-tagged protein was then digested with TEV. 10 IU of TEV protease (Z03030, Genscript) was added to every 3 μg of protein, and the reaction was carried out in 1×TEV Buffer (Z03030, Genscript) overnight at 4°C with gentle stirring (100 rpm). The reaction solution was then passed through a column again, and the flow-through (polymerase that had cleaved the tag) was collected. SDS-PAGE electrophoresis was performed to verify the change in molecular weight. The digested nanoporous monomer protein, polymerase, and sortase were then mixed in molar ratios of 1:3:10, 1:3:30, 3:1:10, and 3:1:30 in 50 mM Tris-HCl (pH 7.8), 5 mM CaCl2, 100 mM NaCl, and 0.2 mM TCEP, respectively, and reacted at 25°C or 30°C. Add SDS loading buffer and denature at 95°C for 5 minutes to terminate the reaction; finally, purify the reaction mixture using SEC and heparin columns and concentrate the protein using an AMICON ULTRA 15mL 50K ultrafiltration column.
[0079] The obtained linker protein was assembled and polymerized with multiple cleaved transmembrane hydrophobic protein monomers to form a hydrophobic transmembrane protein. The assembly molar ratio was linker protein:transmembrane hydrophobic protein monomer = 6:1. The assembly system was incubated overnight at 4°C. Finally, 30% w / v βOG was added to the mixture, with a final βOG concentration of 5% w / v. The final monomer protein and hydrophobic transmembrane protein complex were purified using molecular sieves and a heparin column, and the protein was concentrated using an AMICON ULTRA 15 mL 50K ultrafiltration column to obtain a high-purity protein.
[0080] This invention introduces TEV enzymatic digestion, so that its N-terminus is not simply expressed as polyglycine, but the first amino terminus after cleavage is glycine, and the length can be adjusted, which can be a sequence of more than 5 amino acids.
[0081] Example 2
[0082] The gene expression sequences of SEQ ID NO.1 and SEQ ID NO.2 were transformed into *E. coli* competent cells BL21 (Shanghai Tulugang Biotechnology Co., Ltd., catalog number CC96107). After resistance screening, 5 μL of the inoculum was inoculated into 5 mL of LB broth and incubated overnight at 37°C with shaking. Then, it was transferred to 200 mL of LB broth and incubated at 37°C for 5 h with shaking. OD 600When the concentration of the fusion protein reaches 1, the bacterial culture is removed and cooled at 4°C. After cooling, IPTG is added to a final concentration of 0.6 mM for induction, and the culture is continued overnight at 20°C with shaking. Affinity chromatography is used to purify the monomeric protein and oligomeric monomeric protein using a Ni column or Strep-tagged polymerase. The protein is then concentrated using an AMICON ULTRA 15 mL 50K ultrafiltration column (Millipore, catalog number: UFC905024). Subsequently, the fusion protein is digested with TEV. 10 IU of TEV protease (Z03030, Genscript) is added to every 3 μg of fusion protein. The reaction is carried out in 1×TEV Buffer (Z03030, Genscript) and incubated overnight at 4°C with gentle stirring (100 rpm). The reaction solution is then passed through the column again, and the flow-through (removed polymerase) is collected. SDS-PAGE electrophoresis is performed to verify the change in molecular weight.
[0083] The obtained fusion protein and the monomer of the hydrophobic protein were assembled into a complex protein using liposomes. The molar ratio of fusion protein to transmembrane hydrophobic protein monomer was 8:1. The assembly system was incubated at 37°C for 30-60 minutes. Finally, 30% w / v βOG was added to the mixture, with a final βOG concentration of 5% w / v. The protein was then purified using molecular sieves and a heparin column, and concentrated using an AMICON ULTRA 15 mL 50K ultrafiltration column to obtain the complex protein.
[0084] The obtained protein was subjected to purity and performance evaluation.
[0085] SDS-PAGE protein electrophoresis was used to verify the ligation and the purity of the purified protein. Figure 1 As shown, under the catalytic conditions of Sortase A enzyme, the monomeric proteins of α-HL nanopores bind to Phi29 polymerase, forming linker protein bands. After polymerization with multiple cleaved monomeric proteins of α-HL nanopores to form hydrophobic transmembrane proteins, the resulting complex of monomeric proteins and hydrophobic transmembrane proteins is obtained after purification.
[0086] like Figure 2 As shown, the purified complex proteins of different concentrations in Example 1 were tested by electrophoresis, and the purity of the proteins was relatively high.
[0087] like Figure 3 As shown, the purified complex proteins of different concentrations in Example 2 were tested by electrophoresis, and the purity of the proteins was relatively high.
[0088] like Figure 4As shown, the enzyme activity of the purified complex proteins from the two methods was tested. Using a 200bp single-stranded circular template, primers and dNTPs were added, and the product was extended for 2 hours under 150mM KCl conditions. L2 represents the test result of the complex protein obtained in Example 1; L3 represents the test result of the complex protein obtained in Example 2; M1 refers to the marker for the 1KB Plus DNA Ladder; and M2 refers to the marker for the GeneRuler High Range DNA Ladder. The results show that the complexes obtained using the methods of Example 1 and Example 2 possess DNA polymerase Phi29 activity.
[0089] Obviously, the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. A method for preparing a complex of a monomeric protein and a hydrophobic transmembrane protein, characterized in that, Includes the following steps: Step 1) Prepare protein A comprising the monomeric protein, wherein the C-terminus of the monomeric protein in protein A has a linker sequence for linking with a hydrophobic transmembrane protein; the linker sequence comprises at least 2 amino acids; Prepare protein B containing hydrophobic transmembrane protein monomers; Step 2) Connect protein A and protein B, and polymerize multiple hydrophobic transmembrane protein monomers in protein B to form a hydrophobic transmembrane protein, thereby obtaining a monomeric protein and a hydrophobic transmembrane protein complex.
2. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 1, characterized in that, In step one), the C-terminus of the monomeric protein A is connected to a C-terminal modification sequence, which includes a first length regulation sequence and a recognition site for Sortase A. The N-terminus of the hydrophobic transmembrane protein in protein B is connected to an N-terminal modification sequence, which includes a TEV restriction site and a second length regulation sequence. Protein B has a transition sequence at its C-terminus, which is a purified tag sequence linked to a TEV restriction site; In step two), protein B is first cleaved using TEV protease to obtain cleaved protein B; then protein A and cleaved protein B are reacted with Sortase enzyme to link the first length regulation sequence and the second length regulation sequence to form the linking sequence; and the hydrophobic transmembrane protein monomers in multiple cleaved proteins B are polymerized to form a hydrophobic transmembrane protein, resulting in a monomeric protein and a hydrophobic transmembrane protein complex.
3. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 2, characterized in that, The monomeric protein is DNA polymerase Phi29, the amino acid sequence of protein A is shown in SEQ ID NO.7, and the amino acid sequence of protein B is shown in SEQ ID NO.
8.
4. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 2, characterized in that, The preparation method of the protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into the host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and ultrasonically broken up, and the supernatant is collected; the supernatant is purified to obtain the protein A or protein B.
5. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 2, characterized in that, The nucleotide sequence of expressed protein A is shown in SEQ ID No. 3; the nucleotide sequence of expressed protein B is shown in SEQ ID No.
4.
6. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 1, characterized in that, In step one), protein A is a co-expressed fusion protein formed by the tandem linking of a monomeric protein and a hydrophobic transmembrane protein monomer through the linking sequence. Both protein A and protein B have a tag sequence linked to the C-terminus via a TEV restriction site. In step two), protein A and protein B are first cleaved by TEV protease to obtain cleaved protein A and protein B; then the cleaved protein A and protein B are reacted to polymerize the hydrophobic transmembrane protein monomers in multiple cleaved protein B with the hydrophobic transmembrane protein monomers in protein A to form a hydrophobic transmembrane protein. A complex of monomeric protein and hydrophobic transmembrane protein was obtained.
7. The method for preparing the fusion protein and other hydrophobic transmembrane protein complex according to claim 6, characterized in that, The amino acid sequence of protein A is shown in SEQ ID NO.5, and the amino acid sequence of protein B is shown in SEQ ID NO.
6.
8. The method for preparing the fusion protein and other hydrophobic transmembrane protein complex according to claim 6, characterized in that, The preparation method of the protein A or protein B is as follows: the nucleotide sequence for expressing protein A or protein B is transferred into the host cell to obtain recombinant cells; the recombinant cells are induced to express and the cells are collected; the cells are resuspended and ultrasonically broken up, and the supernatant is collected; the supernatant is purified to obtain the protein A or protein B.
9. The method for preparing the fusion protein and other hydrophobic transmembrane protein complex according to claim 6, characterized in that, The nucleotide sequence of expressed protein A is shown in SEQ ID No. 1; the nucleotide sequence of expressed protein B is shown in SEQ ID No.
2.
10. The method for preparing the monomeric protein and hydrophobic transmembrane protein complex according to claim 1, characterized in that, Step two also includes purifying and concentrating the monomeric protein and hydrophobic transmembrane protein complex.
Citation Information
Cited By
Phi29 DNA polymerase variant and application thereof
CN122012454A
